{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:14:10Z","timestamp":1786986850515,"version":"build-2736575974"},"reference-count":25,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,3]],"date-time":"2024-10-03T00:00:00Z","timestamp":1727913600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100011022","name":"Vertex Pharmaceuticals Incorporated","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011022","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.clinthera.2024.09.024","type":"journal-article","created":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T16:17:57Z","timestamp":1730477877000},"page":"37-43","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Clinical Burden and Healthcare Resource Utilization Associated With Managing Transfusion-dependent \u03b2-Thalassemia in England"],"prefix":"10.1016","volume":"47","author":[{"given":"Chuka","family":"Udeze","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelly F.","family":"Ly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona C.","family":"Ingleby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia D.","family":"Fleming","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah C.","family":"Conner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo","family":"Howard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nanxin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farrukh","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2024.09.024_bib0001","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1750-1172-5-11","article-title":"Beta-thalassemia","volume":"5","author":"Galanello","year":"2010","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.clinthera.2024.09.024_bib0002","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/gim.2016.173","article-title":"Beta-thalassemia","volume":"19","author":"Origa","year":"2017","journal-title":"Genet Med"},{"key":"10.1016\/j.clinthera.2024.09.024_bib0003","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0140-6736(17)31822-6","article-title":"Thalassaemia","volume":"391","author":"Taher","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2024.09.024_bib0004","unstructured":"National Hemoglobinopathy Registry. Annual data report 2020\/21. Accessed August 30, 2023. Available from: https:\/\/nhr.mdsas.com\/wp-content\/uploads\/2022\/03\/NHR_DataReport2021.pdf."},{"key":"10.1016\/j.clinthera.2024.09.024_bib0005","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1111\/bjh.17091","article-title":"Co-morbidities and mortality associated with transfusion-dependent beta-thalassaemia in patients in England: a 10-year retrospective cohort analysis","volume":"191","author":"Jobanputra","year":"2020","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clinthera.2024.09.024_bib0006","unstructured":"Scottish Paediatric and Adult Haemoglobinopathies Network. Annual report 2021\/22. Accessed August 30, 2023. Available from: https:\/\/www.spah.scot.nhs.uk\/wp-content\/uploads\/2021\/11\/2020-21-SPAH-AR-V1.0.pdf."},{"key":"10.1016\/j.clinthera.2024.09.024_bib0007","doi-asserted-by":"crossref","first-page":"100588","DOI":"10.1016\/j.blre.2019.100588","article-title":"Challenges of blood transfusions in beta-thalassemia","volume":"37","author":"Shah","year":"2019","journal-title":"Blood Rev"},{"key":"10.1016\/j.clinthera.2024.09.024_bib0008","series-title":"Guidelines for the Management of Transfusion Dependent Thalassaemia (TDT)","author":"Cappellini","year":"2014"},{"key":"10.1016\/j.clinthera.2024.09.024_bib0009","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1002\/ajh.21049","article-title":"Outcomes, utilization, and costs among thalassemia and sickle cell disease patients receiving deferoxamine therapy in the United States","volume":"83","author":"Delea","year":"2008","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clinthera.2024.09.024_bib0010","doi-asserted-by":"crossref","first-page":"E129","DOI":"10.1002\/ajh.25429","article-title":"Clinical and economic burden of regularly transfused adult patients with beta-thalassemia in the United States: a retrospective cohort study using payer claims","volume":"94","author":"Weiss","year":"2019","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clinthera.2024.09.024_bib0011","doi-asserted-by":"crossref","first-page":"S111","DOI":"10.1016\/j.jval.2023.03.588","article-title":"EE287 Healthcare resource utilization among patients with transfusion-dependent beta-thalassemia in England","volume":"26","author":"Udeze","year":"2023","journal-title":"Value Health"},{"key":"10.1016\/j.clinthera.2024.09.024_bib0012","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1111\/trf.13513","article-title":"Healthcare costs and outcomes of managing beta-thalassemia major over 50 years in the United Kingdom","volume":"56","author":"Weidlich","year":"2016","journal-title":"Transfusion"},{"key":"10.1016\/j.clinthera.2024.09.024_bib0013","unstructured":"Medicine and Healthcare Products Regulatory Agency. Release notes: CPRD aurum March 2022. Accessed August 30, 2023. Available from: https:\/\/cprd.com\/sites\/default\/files\/2022-03\/2022-03%20CPRD%20Aurum%20Release%20Notes.pdf."},{"key":"10.1016\/j.clinthera.2024.09.024_bib0014","doi-asserted-by":"crossref","DOI":"10.1093\/ije\/dyz034","article-title":"Data resource profile: Clinical Practice Research Datalink (CPRD) aurum","volume":"48","author":"Wolf","year":"2019","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.clinthera.2024.09.024_bib0015","unstructured":"National Health Service. Hospital admitted patient care activity 2020-21. Accessed October 2023. Available from: https:\/\/digital.nhs.uk\/data-and-information\/publications\/statistical\/hospital-admitted-patient-care-activity\/2020-21."},{"key":"10.1016\/j.clinthera.2024.09.024_bib0016","unstructured":"Office for National Statistics. How has life expectancy changed over time? Accessed August 30, 2023. Available from: https:\/\/www.ons.gov.uk\/peoplepopulationandcommunity\/birthsdeathsandmarriages\/lifeexpectancies\/articles\/howhaslifeexpectancychangedovertime\/2015-09-09."},{"key":"10.1016\/j.clinthera.2024.09.024_bib0017","unstructured":"Office for National Statistics. Average age at death, by sex, UK. Accessed August 18, 2023. Available from: https:\/\/www.ons.gov.uk\/peoplepopulationandcommunity\/healthandsocialcare\/healthandlifeexpectancies\/datasets\/averageageatdeathbysexuk."},{"key":"10.1016\/j.clinthera.2024.09.024_bib0018","unstructured":"National Institute for Health and Care Excellence (NICE). Single technology appraisal: betibeglogene autotemcel for treating transfusion-dependent beta-thalassaemia. Accessed July 2023. Available from: https:\/\/www.nice.org.uk\/guidance\/gid-ta10334\/documents\/committee-papers."},{"key":"10.1016\/j.clinthera.2024.09.024_bib0019","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1182\/blood-2018-06-818187","article-title":"How I manage medical complications of beta-thalassemia in adults","volume":"132","author":"Taher","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2024.09.024_bib0020","doi-asserted-by":"crossref","first-page":"100594","DOI":"10.1016\/j.blre.2019.100594","article-title":"Management of the aging beta-thalassemia transfusion-dependent population \u2013 the Italian experience","volume":"38","author":"Pinto","year":"2019","journal-title":"Blood Rev"},{"key":"10.1016\/j.clinthera.2024.09.024_bib0021","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1182\/asheducation-2017.1.265","article-title":"Iron overload in thalassemia: different organs at different rates","volume":"2017","author":"Taher","year":"2017","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.clinthera.2024.09.024_bib0022","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1186\/s12913-022-07663-6","article-title":"Healthcare resource utilization and direct costs of transfusion-dependent thalassemia patients in Dubai, United Arab Emirates: a retrospective cost-of-illness study","volume":"22","author":"Alshamsi","year":"2022","journal-title":"BMC Health Serv Res"},{"key":"10.1016\/j.clinthera.2024.09.024_bib0023","doi-asserted-by":"crossref","first-page":"2906","DOI":"10.1111\/trf.16636","article-title":"Relationship between transfusion burden, healthcare resource utilization, and complications in patients with beta-thalassemia in Taiwan: a real-world analysis","volume":"61","author":"Tang","year":"2021","journal-title":"Transfusion"},{"key":"10.1016\/j.clinthera.2024.09.024_bib0024","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1002\/jha2.282","article-title":"Routine management, healthcare resource use and patient and carer-reported outcomes of patients with transfusion-dependent beta-thalassaemia in the United Kingdom: a mixed methods observational study","volume":"2","author":"Shah","year":"2021","journal-title":"EJHaem"},{"key":"10.1016\/j.clinthera.2024.09.024_bib0025","doi-asserted-by":"crossref","first-page":"7734","DOI":"10.1038\/s41598-023-34205-9","article-title":"Health-related quality of life among thalassemia patients in Bangladesh using the SF-36 questionnaire","volume":"13","author":"Hossain","year":"2023","journal-title":"Sci Rep"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014929182400287X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014929182400287X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T14:57:07Z","timestamp":1736348227000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S014929182400287X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S014929182400287X"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2024.09.024","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical Burden and Healthcare Resource Utilization Associated With Managing Transfusion-dependent \u03b2-Thalassemia in England","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2024.09.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Vertex Pharmaceuticals Incorporated. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}